EULAR 2024 recommendations on the use of antirheumatic drugs in reproduction, pregnancy and lactation and comments on them | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1AB1439 UPDATE OF THE EULAR POINTS TO CONSIDER FOR USE OF ANTIRHEUMATIC DRUGS IN REPRODUCTION, PREGNANCY AND LACTATION2024 · 13 citations
2Risk-benefit considerations for antirheumatic drug use in pregnancy, breastfeeding, and male preconception: expert perspectivesOriginal Research · 2026
3Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping ReviewReview · 2025 · 6 citations
4Evaluation of information on pregnancy and lactation in patient information leaflets of antirheumatic drugsOriginal Research · 2025
5The Asia Pacific League of Associations for Rheumatology ( <scp>APLAR</scp> ) Consensus Statements for the Management of Reproductive Issues in Autoimmune Rheumatic DiseasesSystematic Review · 2026 · 4 citations
6EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 updateOriginal Research · 2026 · 116 citations
7AB1463 JOINT MEETINGS ON PREGNANCY COMPLICATED BY RHEUMATIC AND MUSCULOSKELETAL DISEASES: IMPROVEMENT OF CLINICAL COORDINATION AND RESULTS IN 2022-20232024
8EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 updateOriginal Research · 2024 · 389 citations
9Prospects for the use of new antidiabetic drugs in rheumatologyRheumatology Science and Practice · 2026
10Retroperitoneal fibrosis: A contemporary perspective on an old disease, or when there are more questions than answersRheumatology Science and Practice · 2026

More from Rheumatology Science and Practice

More from National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Healthcare of the Russian Federation